Piotr Czekaj, Mateusz Król, Emanuel Kolanko, Łukasz Limanówka, Agnieszka Prusek, Aleksandra Skubis-Sikora, Edyta Bogunia, Bartosz Sikora, Mateusz Hermyt, Marcin Michalik, Aniela Grajoszek, Jacek Pająk
BACKGROUND: In humans, chronic liver disease (CLD) is a serious clinical condition with many life-threatening complications. Currently, there is no therapy to stop or slow down the progression of liver fibrosis. Experimental mouse models of CLD, induced by repeated intraperitoneal injections of carbon tetrachloride (CCL4) and D-galactosamine (D-GalN), can be used to evaluate therapies that cannot be performed in humans. A major drawback of these animal models is the different dynamics of liver fibrosis progression depending on the animal strain, administered hepatotoxin, its dose, duration of intoxication, and frequency of injections...
May 9, 2023: Frontiers in Bioscience (Landmark Edition)